ADVERTISEMENT
Brian J. Del Buono, PhD, is a director in the Biotechnology/Chemical Group at Sterne, Kessler, Goldstein & Fox
The introduction of two rival bills has intensified the long-simmering debate on biosimilars regulation in the US.